{"entity":{"id":"nct05609370","kind":"trial","name":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ","aka":[],"tldr":"A phase 1/2 trial of Tislelizumab in colorectal cancer, run by BeiGene, active and no longer recruiting.","summary":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05609370 by BeiGene, with 113 participants enrolled, started 2023-01-29 and due to reach its primary completion in 2025-05-23. Interventions recorded: Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP). Conditions listed: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05609370","url":"https://clinicaltrials.gov/study/NCT05609370"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05609370","phase":"1/2","setting":"A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer","sponsor":"BeiGene","started":"2023-01-29","startedType":"actual","yearReported":2026,"enrolled":113,"enrolledBasis":"registry","outcomes":[{"endpoint":"Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C","primary":true,"unit":"months","arms":[{"name":"Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine","n":18,"note":"Values could not be estimated due to an insufficient number of events; Figures from the ClinicalTrials.gov results section (first posted 2026-06-30), not from a publication"},{"name":"Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine","n":16,"value":4.4,"note":"95% CI 2.1 to NA"}],"hr":0.37,"ci":[0.1,1.33],"source":"https://clinicaltrials.gov/study/NCT05609370?tab=results"}]},"route":"/trials/nct05609370/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}